Clinical Trial Detail

NCT ID NCT02360579
Title Study of LN-144, Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (LN-144)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Iovance Biotherapeutics, Inc.
Indications

melanoma

Therapies

LN-144

Age Groups: adult senior

No variant requirements are available.